Zai Lab Q4 2024 revenue $109.1M (+66% YoY); guides FY2025 revenue $560-590M

Zai Lab Ltd

2024-FY EPS reported -$0.26 revenue$398,988,000

Total revenues $399.0M for FY2024, up 50% YoY; product revenue $397.6M, up 49% YoY.
VYVGART franchise net revenue $93.6M in first full year; ZEJULA $187.1M (+11% YoY); NUZYRA $43.2M (+99% YoY).
Loss from operations decreased 23% to $282.1M for FY2024; net loss per ADS $2.60 vs $3.46 in 2023.
Cash position $879.7M as of Dec 31, 2024; expects adjusted profitability (non-GAAP) in Q4 2025.
ZL-1310 (DLL3 ADC) SCLC trial showed 74% ORR; NDA accepted for KarXT in schizophrenia in China.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.